Boundless Bio Inc
BOLD1.220USD
-0.050-3.94%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
27.31MMarket Cap
LossP/E TTM
More Details of Boundless Bio Inc Company
Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that address the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. The Company’s lead therapeutic candidate ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in oncogene amplified preclinical cancer models, including those enabled by ecDNA, and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its next program is directed at a previously undrugged kinesin target.
Boundless Bio Inc Info
Ticker SymbolBOLD
Company nameBoundless Bio Inc
IPO dateMar 28, 2024
CEOHornby (Zachary D)
Number of employees64
Security typeOrdinary Share
Fiscal year-endMar 28
Address10955 Alexandria Way
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18587669912
Websitehttps://boundlessbio.com/
Ticker SymbolBOLD
IPO dateMar 28, 2024
CEOHornby (Zachary D)
Company Executives of Boundless Bio Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Senior Vice President - Finance, Controller and Corporate Treasurer
Senior Vice President - Finance, Controller and Corporate Treasurer
--
--
Dr. James G. (Jamie) Christensen, Ph.D.
Dr. James G. (Jamie) Christensen, Ph.D.
Independent Director
Independent Director
--
--
Dr. Nancy C. Whiting, Pharm.D.
Dr. Nancy C. Whiting, Pharm.D.
Independent Director
Independent Director
--
--
Dr. Christine Brennan, Ph.D.
Dr. Christine Brennan, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Lew
Ms. Jennifer Lew
Independent Director
Independent Director
--
--
Dr. Robert (Bob) Doebele, M.D., Ph.D.
Dr. Robert (Bob) Doebele, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
653.48K
--
Mr. Zachary D. Hornby
Mr. Zachary D. Hornby
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Christian (Chris) Hassig, Ph.D.
Dr. Christian (Chris) Hassig, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Kristina M. Burow
Ms. Kristina M. Burow
Independent Director
Independent Director
--
--
Mr. David Hinkle
Mr. David Hinkle
Senior Vice President - Finance, Controller and Corporate Treasurer
Senior Vice President - Finance, Controller and Corporate Treasurer
--
--
Dr. James G. (Jamie) Christensen, Ph.D.
Dr. James G. (Jamie) Christensen, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.82%
ARCH Venture Partners
12.03%
Bayer HealthCare LLC
7.22%
Citadel Advisors LLC
6.40%
Nextech Invest, Ltd.
5.49%
Other
55.04%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
13.82%
ARCH Venture Partners
12.03%
Bayer HealthCare LLC
7.22%
Citadel Advisors LLC
6.40%
Nextech Invest, Ltd.
5.49%
Other
55.04%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.77%
Venture Capital
12.16%
Hedge Fund
11.37%
Investment Advisor/Hedge Fund
10.14%
Corporation
7.22%
Individual Investor
4.18%
Research Firm
0.10%
Other
31.06%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
132
12.33M
76.87%
--
2025Q3
132
12.33M
76.87%
-167.22K
2025Q2
131
12.49M
78.53%
-3.25M
2025Q1
121
15.75M
77.89%
-1.62M
2024Q4
112
15.68M
77.92%
-298.26K
2024Q3
101
16.92M
79.18%
-605.35K
2024Q2
82
17.52M
79.23%
-1.06M
2024Q1
50
18.02M
0.00%
+18.02M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
3.12M
13.94%
-32.67K
-1.04%
Jun 30, 2025
ARCH Venture Partners
2.69M
12.03%
--
--
Apr 25, 2025
Bayer HealthCare LLC
1.62M
7.22%
--
--
Apr 25, 2025
Citadel Advisors LLC
830.94K
3.71%
--
--
Jun 30, 2025
Nextech Invest, Ltd.
1.23M
5.49%
--
--
Jun 30, 2025
Sectoral Asset Management Inc.
678.57K
3.03%
--
--
Jun 30, 2025
Lim (Jonathan E)
653.48K
2.92%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
481.27K
2.15%
-105.17K
-17.93%
Jun 30, 2025
Wellington Management Company, LLP
556.23K
2.48%
--
--
Jun 30, 2025
Stonepine Capital Management, LLC
106.17K
0.47%
+106.17K
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Boundless Bio Inc?
The top five shareholders of Boundless Bio Inc are:
Fidelity Management & Research Company LLC holds 3.12M shares, accounting for 13.94% of the total shares.
ARCH Venture Partners holds 2.69M shares, accounting for 12.03% of the total shares.
Bayer HealthCare LLC holds 1.62M shares, accounting for 7.22% of the total shares.
Citadel Advisors LLC holds 830.94K shares, accounting for 3.71% of the total shares.
Nextech Invest, Ltd. holds 1.23M shares, accounting for 5.49% of the total shares.
Fidelity Management & Research Company LLC holds 3.12M shares, accounting for 13.94% of the total shares.
ARCH Venture Partners holds 2.69M shares, accounting for 12.03% of the total shares.
Bayer HealthCare LLC holds 1.62M shares, accounting for 7.22% of the total shares.
Citadel Advisors LLC holds 830.94K shares, accounting for 3.71% of the total shares.
Nextech Invest, Ltd. holds 1.23M shares, accounting for 5.49% of the total shares.
What are the top three shareholder types of Boundless Bio Inc?
The top three shareholder types of Boundless Bio Inc are:
Fidelity Management & Research Company LLC
ARCH Venture Partners
Bayer HealthCare LLC
Fidelity Management & Research Company LLC
ARCH Venture Partners
Bayer HealthCare LLC
How many institutions hold shares of Boundless Bio Inc (BOLD)?
As of 2025Q4, 132 institutions hold shares of Boundless Bio Inc, with a combined market value of approximately 12.33M, accounting for 76.87% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Boundless Bio Inc?
In --, the -- business generated the highest revenue for Boundless Bio Inc, amounting to -- and accounting for --% of total revenue.
